Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to test whether the attention-enhancing effects of low-dose nicotine
can be enhanced by the drug galantamine, FDA-approved for the treatment of Alzheimer's
disease. This proof-of-principle study is performed in healthy non-smokers and involves two
single exposures to a nicotine patch (7 mg/24 hrs) and two single exposures to galantamine (4
mg). The dose of galantamine is substantially lower than the clinical dose range of 16-24
mg/day. The hypothesis is that performance-enhancing effects of nicotine are greater in the
presence of this low dose of galantamine.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore